洛匹那韦/利托那韦加 EF 的 III 期、随机、开放标签比较-猫眼课题宝

洛匹那韦/利托那韦加 EF 的 III 期、随机、开放标签比较

批准号：

7606755

负责人：

MARGRIT E CARLSON

金额：

$0.77万

依托单位：

UNIVERSITY OF CALIFORNIA LOS ANGELES

依托单位国家：

美国

项目类别：

财政年份：

2007

资助国家：

美国

项目状态：

已结题

起止时间：

2007-02-21 至 2007-11-30

来源：

https://reporter.nih.gov/project-details/7606755

关键词：

Computer Retrieval of Information on Scientific Projects Database Failure Funding Grant Institution Label Lamivudine Lopinavir/Ritonavir Phase Randomized Research Research Personnel Resources Source Time Toxic effect Treatment Protocols United States National Institutes of Health Zidovudine

项目摘要

项目成果

MARGRIT E CARLSON的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives are: 1. To compare the time to virologic failure pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. (See Section 3.5 for definition of virologic failure.) 2. To compare the time to regimen completion pairwise between the three treatment groups: LPV/r plus EFV, LPV/r plus d4T XR (or ZDV) plus 3TC, and EFV plus d4T XR (or ZDV) plus 3TC. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. See sections 3.5 and 3.6 for definition of virologic failure and regimen completion.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文